Navigation Links
Arthrosurface Raises $4 Million of Preferred Equity Financing
Date:2/28/2008

FRANKLIN, Ma., Feb. 28 /PRNewswire-FirstCall/ -- Arthrosurface, Inc. (http://www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, has announced that it has raised approximately $4 million in its latest Preferred Stock Series F equity financing. Funded by Boston Millennia Partners and private investors, to date, the company has raised approximately $31 million of equity capital. "The Series F funding is earmarked to support our new product launches, expansion of the company's direct field sales team and to provide ongoing working capital," said Steve Ek, COO. "We now have greater resources to provide for the people and working capital to support the continued growth of the business."

Arthrosurface is entering its fourth year of commercial launch with approximately 7,000 devices implanted by more than 2,000 surgeon users in the various joint applications of the HemiCAP(R) system. Last year, US implant sales were up 55% with strong growth across all key product lines. In particular, sales of the company's first US knee device, the Patello-Femoral HemiCAP(R), grew 237% year on year. "We have found that within the first year of clinical launch, implanting surgeons closely monitor patient progress and, once they have confirmed positive results, sales begin to rise significantly. An excellent example of this was our great toe product. Cases went from a few hundred in the first year to thousands within two years. We expect similar adoption with the release of our new products," commented company president Steve Tallarida.

The company's HemiCAP(R) systems consist of a range of contoured articular prosthetics and instrumentation intended for the repair of significant lesions and cartilage damage in the major joints. Arthrosurface continues to grow its line of shoulder, great toe, patello-femoral and hip products in the US. These same products are sold in Europe in addition to its knee femoral condyle and talar dome devices.

The HemiCAP(R) system provides a less invasive alternative servicing the joint reconstruction market with its resurfacing systems. "We believe there is a growing body of patients that have damaged cartilage seeking medical options that will enable them to maintain their active lifestyles. These patients will consider surgical treatment provided that recovery is relatively easy and their future medical options remain open. We believe that this is the new Millennium Patient(TM)," said Lester Fehr, VP Sales & Marketing. "Today's patient is a more demanding and educated consumer. For Arthrosurface, we believe that this is our patient."


'/>"/>
SOURCE Arthrosurface, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
2. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
3. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
4. Primera Biosystems Raises $21 Million in Series B Private Round
5. Cellectar, Inc. Raises $13 Million in Private Offering
6. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
7. Anesiva Raises $45 Million in Common Stock Offering
8. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
9. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
10. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
11. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):